Evaluation of 18F-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma

The Evaluation of the 6-[18F]Fluoro-levo-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma

Neuroblastic tumors are childhood neoplasms that possess amino acid decarboxylase (AADC) activity and Meta-iodobenzylguanidine(MIBG), they can theoretically be imaged by (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) and (123)I-Meta-iodobenzylguanidine((123)I-MIBG) PET, they are new and specific diagnostic and follow-up tools for neuroendocrine tumors. In this study, we explored the accuracy and clinical role of (18)F-FDOPA and (123)I-MIBG PET in neuroblastic tumors.

METHODS:

Patients with tissue-proven neuroblastic tumors receiving (18)F-FDOPA PET or (123)I-MIBG at initial diagnosis or during follow-ups were enrolled. The sensitivity and specificity of (18)F-FDOPA or (123)I-MIBG PET were compared to each other and compared to(18)F-FDG PET, using tumor histology as the standard.

Inclusion Criteria:

• (1) Diagnosed by clinical criteria(one of below)

  1. Proved as Neuroblastoma by a pathological section
  2. Bone meta with 24 hrs urine VMA(Vanillylmandelic acid )or HVA (Homovanillic acid) elevated
  3. CT or MRI found tumor around adrenal gland or Neuroblastic tumor

• (2) Age between 0-30 years old，Body weight over 2.5kg

• (3) Signed Inform Consent Form

Exclusion Criteria:

• (1)AST and ALT > 200U/L、Cre > 2.5mg/dl
• (2)Allerg to 18F-dopa、123I-MIBG
• (3)Subject not fit this study(assessed by PI)
• (4)No more need to arrenge PET because disease progress, assessed by VS